Symbicort Turbuhaler

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2002-2016
012320022016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
BACKGROUND Therapeutic equivalence of Budesonide/formoterol Easyhaler compared to Symbicort Turbuhaler has been previously… (More)
Is this relevant?
2006
2006
The dose emitted from dry powder inhalers may be inhalation flow-dependent. Using an ex vivo method, the Electronic Lung, we have… (More)
Is this relevant?
2005
2005
Dry powder inhalers (DPIs) are increasingly being used for the treatment of asthma and COPD. A potential drawback is that DPIs… (More)
Is this relevant?
2005
2005
OBJECTIVE The use of combination inhaled corticosteroid/long-acting beta-agonist therapy within the framework of a self… (More)
Is this relevant?
Review
2004
Review
2004
Budesonide and formoterol have been combined in a single dry powder device, Symbicort Turbuhaler (budesonide/formoterol 160/9-640… (More)
Is this relevant?
2003
2003
BACKGROUND A budesonide/formoterol single inhaler has been developed for convenient treatment of patients whose asthma is… (More)
Is this relevant?
2003
2003
This open, multinational, randomised, parallel-group, six-month extension conducted in the Swedish centres of a previous six… (More)
Is this relevant?
2003
2003
This randomised, double-blind, double-dummy, crossover, placebo-controlled study assessed the acute tolerability of budesonide… (More)
Is this relevant?
Review
2002
Review
2002
Symbicort is a novel asthma product containing both budesonide and formoterol in a single inhaler, Turbuhaler. Budesonide is a… (More)
Is this relevant?
Review
2002
Review
2002
Asthma is now widely recognized as a chronic inflammatory condition of the airways that requires early pharmacological treatment… (More)
Is this relevant?